European patients with non-Hodgkin lymphoma (NHL) are more likely to be prescribed a rituximab (MabThera, EU; Rituxan, US) biosimilar if they are in better overall health, have indolent histology, and have follicular lymphoma, according to a study presented at the 2018 ASCO Annual Meeting.
Franceschetti A, Caldeira R. Treatment approach for non-Hodgkin lymphoma patients since first biosimilars of rituximab approved in EU5. J Clin Oncol. 2018;36 (suppl; abstr 112).
... to read the full story